This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Nanjing MeiRui Pharma Co., Ltd.
Nanjing MeiRui Pharma Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in Nanjing, China. Established in 2003, the company has rapidly expanded its operations across major regions in Asia and beyond, focusing on the development and manufacturing of high-quality pharmaceutical products. Specialising in active pharmaceutical ingredients (APIs) and finished dosage forms, Nanjing MeiRui Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of generic medications and specialty pharmaceuticals, which are distinguished by their efficacy and safety profiles. With a strong market position, Nanjing MeiRui Pharma has achieved significant milestones, including various certifications and partnerships that underscore its reputation for excellence in the pharmaceutical sector.
DitchCarbon Score
How does Nanjing MeiRui Pharma Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nanjing MeiRui Pharma Co., Ltd.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nanjing MeiRui Pharma Co., Ltd., headquartered in China, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, and as such, it inherits emissions data and climate commitments from its parent organisation. While no absolute emissions figures are provided, Nanjing MeiRui Pharma is aligned with GSK plc's sustainability initiatives, which include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These commitments reflect a robust approach to reducing carbon emissions across their operations, although specific reduction targets for Nanjing MeiRui Pharma have not been disclosed. The company is also involved in the Climate Pledge and other initiatives led by GSK plc, indicating a commitment to addressing climate change and reducing its carbon footprint. However, without specific emissions data or reduction targets, the exact impact of these initiatives on Nanjing MeiRui Pharma's operations remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nanjing MeiRui Pharma Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
